Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4

Autor: Marloes Stam, Camiel A Wijngaarde, Bart Bartels, Fay-Lynn Asselman, Louise A M Otto, Laura E Habets, Ruben P A van Eijk, Bas M Middelkoop, H Stephan Goedee, Janke F de Groot, Kit C B Roes, Marja A G C Schoenmakers, Edward E S Nieuwenhuis, Inge Cuppen, Leonard H van den Berg, Renske I Wadman, W Ludo van der Pol

Publikováno v: Brain Communications, 5
Brain Communications, 5, 1

Hereditary proximal spinal muscular atrophy causes weakness and increased fatigability of repetitive motor functions. The neuromuscular junction is anatomically and functionally abnormal in patients with spinal muscular atrophy. Pharmacological impro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21143b70317859320feacf01880264ea
http://hdl.handle.net/2066/289329

Prognosis for patients with amyotrophic lateral sclerosis : development and validation of a personalised prediction model

Autor: Christopher J McDermott, Philip Van Damme, Beatrice Stubendorff, Markus Weber, Sonja Körner, Andrea Calvo, Christopher Shaw, Martin R Turner, Mark Heverin, Annelien L. Bredenoord, Orla Hardiman, Susanne Petri, Karel G.M. Moons, Bas M. Middelkoop, Philippe Couratier, Angela Rosenbohm, Mamede de Carvalho, Albert C. Ludolph, Wouter van Rheenen, Ruben P A van Eijk, Hannah Hollinger, Leonard H. van den Berg, Alexander G. Thompson, Mbombe Kazoka, Adriano Chiò, Anne E. Visser, A. Rödiger, A. Gunkel, Sarah Martin, Philippe Corcia, Joke van Vugt, Xenia Kobeleva, Thomas P. A. Debray, James Rooney, Pamela J. Shaw, Annelot M. Dekker, Ammar Al-Chalabi, Marta Gromicho, Alice Vajda, Kevin Talbot, Thomas M. Ringer, Helma Sommer, Julian Grosskreutz, Susana Pinto, Michael A van Es, Henk Jan Westeneng, Jan H. Veldink

Publikováno v: Lancet Neurology, 17(5), 423. Lancet Publishing Group
Lancet Neurology
Lancet Neurology, Elsevier, 2018, 17 (5), pp.423-433. 〈10.1016/S1474-4422(18)30089-9〉
The Lancet Neurology
The Lancet Neurology, Elsevier, 2018, 17 (5), pp.423-433. ⟨10.1016/S1474-4422(18)30089-9⟩
Westeneng, H-J, Debray, T P A, Visser, A E, van Eijk, R P A, Rooney, J P K, Calvo, A, Martin, S, McDermott, C J, Thompson, A G, Pinto, S, Kobeleva, X, Rosenbohm, A, Stubendorff, B, Sommer, H, Middelkoop, B M, Dekker, A M, van Vugt, J J F A, van Rheenen, W, Vajda, A, Heverin, M, Kazoka, M, Hollinger, H, Gromicho, M, Körner, S, Ringer, T M, Rödiger, A, Gunkel, A, Shaw, C E, Bredenoord, A L, van Es, M A, Corcia, P, Couratier, P, Weber, M, Grosskreutz, J, Ludolph, A C, Petri, S, de Carvalho, M, Van Damme, P, Talbot, K, Turner, M R, Shaw, P J, Al-Chalabi, A, Chiò, A, Hardiman, O, Moons, K G M, Veldink, J H & van den Berg, L H 2018, ' Prognosis for patients with amyotrophic lateral sclerosis : development and validation of a personalised prediction model ', Lancet Neurology . https://doi.org/10.1016/S1474-4422(18)30089-9

Summary\ud Background\ud Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, fatal motor neuron disease with a variable natural history. There are no accurate models that predict the disease course and outcomes, which complicates risk

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::274b7a0d0704467cc40ed61083bed92b
https://dspace.library.uu.nl/handle/1874/376979